Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The aim of the study was to compare serum sclerostin levels in human immunodeficiency virus (HIV)-infected patients and healthy controls, and to evaluate their relationship with bone turnover markers (BTM) and bone mineral density (BMD). Methods: We prospectively studied 33 HIV treatment-naive patients and 63 healthy individuals; match ed for age and sex. Serum sclerostin levels, BTM, BMD were measured. Viral load and cluster of differentiation 4 (CD4) levels were also assessed in HIV-infected patients. Results: The mean±standard deviation (SD) age of sample was 37.6±10.3 years (range, 19 to 59 years). Of the 96 subjects, 58 (60.4%) were male and 38 (39.6%) were female. Infection with HIV is associated with significant reduction in serum sclerostin levels (HIV-infected: 39.4±28.3 vs. non HIV: 76.6±15.7 pmol/L; P<0.001) and a decrease in BMD at femoral neck and lumbar spine compared to healthy controls. Sclerostin however was not correlated with BMD and was not related to age, generally a strong correlation. There were no significant correlations between sclerostin and BTM (P>0.05). Conclusions: These findings suggest that untreated HIV and the resulting immune deficiency and/or systemic inflammation could be an important regulator of serum sclerostin in this population.
Abstract
Background: The aim of the study was to compare serum sclerostin levels in human immunodeficiency virus (HIV)-infected patients and healthy controls, and to evaluate their relationship with bone turnover markers (BTM) and bone mineral density (BMD). Methods: We prospectively studied 33 HIV treatment-naive patients and 63 healthy individuals; match ed for age and sex. Serum sclerostin levels, BTM, BMD were measured. Viral load and cluster of differentiation 4 (CD4) levels were also assessed in HIV-infected patients. Results: The mean±standard deviation (SD) age of sample was 37.6±10.3 years (range, 19 to 59 years). Of the 96 subjects, 58 (60.4%) were male and 38 (39.6%) were female. Infection with HIV is associated with significant reduction in serum sclerostin levels (HIV-infected: 39.4±28.3 vs. non HIV: 76.6±15.7 pmol/L; P<0.001) and a decrease in BMD at femoral neck and lumbar spine compared to healthy controls. Sclerostin however was not correlated with BMD and was not related to age, generally a strong correlation. There were no significant correlations between sclerostin and BTM (P>0.05). Conclusions: These findings suggest that untreated HIV and the resulting immune deficiency and/or systemic inflammation could be an important regulator of serum sclerostin in this population.
참고문헌 (31)
- Yong MK, "Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients", J Acquir Immune Defic Syndr, 57, pp.205~210 (2011)
- Borderi M, "Metabolic bone disease in HIV infection", AIDS, 23, pp.1297~1310 (2009)
- Cazanave C, "Reduced bone mineral density in HIV-infected patients : prevalence and associated factors", AIDS, 22, pp.395~402 (2008)
- Arnsten JH, "Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection", AIDS, 21, pp.617~623 (2007)
- Fausto A, "Potential predictive factors of osteoporosis in HIV-positive subjects", Bone, 38, pp.893~897 (2006)
- Ardawi MS, "Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study", J Clin Endocrinol Metab, 97, pp.3691~3699 (2012)
- You L, "Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading", Bone, 42, pp.172~179 (2008)
- Rachner TD, "Osteoporosis: now and the future", Lancet, 377, pp.1276~1287 (2011)
- Li X, "Sclerostin binds to LRP5", 6 and antagonizes canonical Wnt signaling, 2005, pp.280, 19883~19887
- Brunkow ME, "Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein", Am J Hum Genet, 68, pp.577~589 (2001)
- Horowitz MC, "Sclerostin : a new mediator of crosstalk between the skeletal and immune systems", J Bone Miner Res, 27, pp.1448~1450 (2012)
- Takayanagi H, "Osteoimmunology : shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)
- Cain CJ, "Absence of sclerostin adversely affects B-cell survival", J Bone Miner Res, 27, pp.1451~1461 (2012)
- Bellido T, "Effects of PTH on osteocyte function", Bone, 54, pp.250~257 (2013)
- Mirza FS, "Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women", J Clin Endocrinol Metab, 95, pp.1991~1997 (2010)
- Robling AG, "Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost", sclerostin, 2008, pp.283, 5866~5875
- Frings-Meuthen P, "Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men", J Musculoskelet Neuronal Interact, 13, pp.45~52 (2013)
- Ardawi MS, "Determinants of serum sclerostin in healthy pre-and postmenopausal women", J Bone Miner Res, 26, pp.2812~2822 (2011)
- Hui SL, "Universal standardization of bone density measurements : a method with optimal properties for calibration among several instruments", J Bone Miner Res, 12, pp.1463~1470 (1997)
- Lu Y, "Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle", Osteoporos Int, 12, pp.438~444 (2001)
- Damilakis J, "Quality assurance and dosimetry in bone densitometry", Radiol Clin North Am, 48, pp.629~640 (2010)
- World Health Organization, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- Amrein K, "Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults", J Clin Endocrinol Metab, 97, pp.148~154 (2012)
- Morse LR, "Association between sclerostin and bone density in chronic spinal cord injury", J Bone Miner Res, 27, pp.352~359 (2012)
- Morse LR, "Sclerostin : a candidate biomarker of SCI-induced osteoporosis", Osteoporos Int, 24, pp.961~968 (2013)
- Madani TA, "Epidemiology of the human immunodeficiency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective", BMC Infect Dis, 4, pp.25~ (2004)
- Mazroa MA, "HIV case notification rates in the Kingdom of Saudi Arabia over the past decade (2000-2009)", PLoS One, 7, pp.e45919~ (2012)
- McMichael AJ, "Cellular immune responses to HIV", Nature, 410, pp.980~987 (2001)
- World Health Organization, "Interim WHO clinical staging of HIV", AIDS and HIV, World Health Organization, pp.2005, ~
- Garnero P, "Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study", Osteoporos Int, 24, pp.489~494 (2013)
- E. González-Reimers, "Serum Sclerostin in Hepatitis C Virus Infected Patients", 대한골대사학회지, 21(1), pp.69~75 (2014), 대한골대사학회